Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: Risk calculators for real-world decision-making

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chen, Anders ^a   Dowdy, David W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CONDOM; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; MEN WHO HAVE SEX WITH MEN; NUMBERS NEEDED TO TREAT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; QUALITY ADJUSTED LIFE YEAR;

EID: 84930809943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108742     Document Type: Article

References (42)

1. HIV Among Gay and Bisexual Men (n.d.) Centers for Disease Control and Prevention. Available: http://www.cdc.gov/hiv/risk/gender/msm/facts/index.html Accessed 2014 April 18.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599. doi: 10.1056/nejmoa1011205
3. US Public Health Service, Centers for Disease Control and Prevention (2014) Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the United States-2014 Clinical Practice Guideline.
4. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839. doi: 10.1097/qad.0b013e32830e00f5
5. Juusola JL, Brandeau ML, Owens DK, Bendavid E (2012) The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 156: 541-550. doi: 10.7326/0003-4819-156-8-201204170-00004
6. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL (2011) The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr 58: e51-52. doi: 10.1097/qai.0b013e31822b74fe
7. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815. doi: 10.1086/597095
8. Schackman BR, Eggman AA (2012) Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS 7: 587-592. doi: 10.1097/coh.0b013e3283582c8b
9. Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM (2014) Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada. Clin Infect Dis 58: 704-712. doi: 10.1093/cid/cit796
10. Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, et al. (2012) A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 7: e40603. doi: 10.1371/journal.pone.0040603
11. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT (2010) Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 54: 548-555. doi: 10.1097/qai.0b013e3181e19a54
12. Saberi P, Gamarel KE, Neilands TB, Comfort M, Sheon N, et al. (2012) Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS One 7: e50061. doi: 10.1371/journal.pone.0050061
13. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R (2012) Attitudes and program preferences of African-American urban young adults about preexposure prophylaxis (PrEP). AIDS Educ Prev 24: 408-421. doi: 10.1521/aeap.2012.24.5.408
14. Hosek S, Siberry G, Bell M, Lally M, Kapogiannis B, et al. (2012) The Acceptability and Feasibility of an HIV Pre-Exposure Prophylaxis (PrEP) Trial with Young Men who Have Sex with Men (YMSM). J Acquir Immune Defic Syndr. doi: 10.1097/qai.0b013e3182801081
15. Davidson MH (2002) Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol 89: 8C-20C discussion 20C-22C. doi: 10.1016/s0002-9149(02)02223-3
16. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD (2005) Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 22: 554-562. doi: 10.1111/j.1464-5491.2005.01494.x
17. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, et al. (1999) Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150: 306-311. doi: 10.1093/oxfordjournals.aje.a010003
18. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, et al. (2010) Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 24: 907-913. doi: 10.1097/qad.0b013e3283372d90
19. Xiridou M, Geskus R, De Wit J, Coutinho R, Kretzschmar M (2003) The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam. AIDS 17: 1029-1038. doi: 10.1097/00002030-200305020-00012
20. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, et al. (2012) Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 205: 358-365. doi: 10.1093/infdis/jir747
21. Xu F, Sternberg MR, Markowitz LE (2010) Men who have sex with men in the United States: demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: results from National Health and Nutrition Examination Survey 2001-2006. Sex Transm Dis 37: 399-405. doi: 10.1097/olq.0b013e3181ce122b
22. Baggaley RF, White RG, Hollingsworth TD, Boily MC (2013) Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology 24: 110-121. doi: 10.1097/ede.0b013e318276cad7
23. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505. doi: 10.1056/nejmoa1105243
24. Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, et al. (2013) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 4: CD009153. doi: 10.1002/14651858.cd009153.pub3
25. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep 60: 1618-1623.
26. Weller S, Davis K (2002) Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev: CD003255.
27. Fleming DT, Wasserheit JN (1999) From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75: 3-17. doi: 10.1136/sti.75.1.3
28. Mimiaga MJ, Helms DJ, Reisner SL, Grasso C, Bertrand T, et al. (2009) Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex Transm Dis 36: 507-511. doi: 10.1097/olq.0b013e3181a2ad98
29. Sullivan PS, Salazar L, Buchbinder S, Sanchez TH (2009) Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS 23: 1153-1162. doi: 10.1097/qad.0b013e32832baa34
30. Prevalence and awareness of HIV infection among men who have sex with men - 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 59: 1201-1207.
31. Gebo KA, Fleishman JA, Conviser R, Hellinger J, Hellinger FJ, et al. (2010) Contemporary costs of HIV healthcare in the HAART era. AIDS 24: 2705-2715. doi: 10.1097/qad.0b013e32833f3c14
32. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, et al. (2006) The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 44: 990-997. doi: 10.1097/01.mlr.0000228021.89490.2a
33. Owusu-Edusei K Jr, Chesson HW, Gift TL, Tao G, Mahajan R, et al. (2013) The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 40: 197-201. doi: 10.1097/olq.0b013e318285c6d2
34. (2012) Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2011. Atlanta, GA: US Department of Health and Human Services.
35. Tengs TO, Lin TH (2002) A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 22: 475-481. doi: 10.1177/0272989x02238300
36. The Global Burden of Disease 2004 update: Disability Weights for Diseases and Conditions. The World Health Organization (n.d.) Available: http://www.who.int/healthinfo/global-burden-disease/GBD2004-DisabilityWeights.pdf Accessed 2014February 10.
37. Kent CK, Chaw JK, Wong W, Liska S, Gibson S, et al. (2005) Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 41: 67-74. doi: 10.1086/430704
38. Morris SR, Klausner JD, Buchbinder SP, Wheeler SL, Koblin B, et al. (2006) Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study. Clin Infect Dis 43: 1284-1289. doi: 10.1086/508460
39. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL (2004) The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 36: 11-19. doi: 10.1111/j.1931-2393.2004.tb00003.x
40. Baggaley RF, White RG, Boily MC (2010) HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 39: 1048-1063. doi: 10.1093/ije/dyq057
41. Bureal of Labor Statistics. Medical Care Component of the Consumer Price Index.
42. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258. doi: 10.1001/jama.276.15.1253